Eyedaptic has introduced the EYE7, its newest AI-powered smart glasses designed to help patients with age-related macular degeneration (AMD) and diabetic retinopathy see more clearly through artificial intelligence and augmented reality technology. The lightweight device, weighing less than 3 ounces, builds on previous generations with enhanced vision capabilities, a sleeker design, and a new virtual assistant called Eva that can read text, recognize objects, and perform web searches in over 99 languages .

How Do These AI Glasses Actually Help People With Vision Loss?

The EYE7 works through Eyedaptic's proprietary Simulated Natural Vision Software, which uses pixel manipulation to optimize a patient's remaining peripheral vision. Rather than replacing lost vision entirely, the technology simulates clearer vision by enhancing what functional sight remains. The glasses come with several practical features designed for daily life :

• Auto-Zoom Mode: Automatically magnifies text in various situations, making reading easier without manual adjustment
• Contrast Enhancement: Improves image clarity by adjusting contrast levels for better visibility in different lighting conditions
• Facial Detection: Recognizes faces in the user's environment, helping with social interactions and navigation
• 2-in-1 Design: Functions as both wearable glasses and a handheld magnifier for flexible use
• EyeSwitch Technology: Enables hands-free control through eye movements and gestures

What's New in the EYE7 Compared to Earlier Models?

Eyedaptic has been refining its vision-enhancement technology for years, releasing the EYE2, EYE3, EYE4, EYE5, and EYE6 before the EYE7. The EYE6, launched in 2024, introduced Ivy, a generative visual assistant available in 99 languages. The EYE7 takes this further with Eva, a more capable virtual assistant that offers additional features beyond what Ivy provides .

The EYE7 brings several meaningful improvements over its predecessors. The device features a lighter-weight, sleeker design that's more comfortable for extended daily wear. Battery life has been extended, reducing the need for frequent charging. The glasses also include customizable visual modes with intuitive controls, allowing users to adjust settings based on their specific needs and preferences. Users can choose between Ivy or Eva as their virtual assistant, with Eva offering more advanced capabilities like real-time voice control and web-enabled searches for current information .

One significant advantage of the EYE7 is that it can accommodate changing prescriptions through adjustable prescription inserts. The glasses can also be worn over a patient's existing eyeglasses if preferred, making them accessible to people who already wear corrective lenses. Additionally, Eyedaptic plans to roll out Eva through a remote software upgrade, meaning current users won't need to purchase new hardware to access the enhanced assistant .

What Regulatory Status Do These Glasses Have?

According to Eyedaptic, the EYE7 and its predecessor models are classified as Class I exempt medical devices, meaning they present minimal risk of harm and do not require premarket notification or FDA approval such as a 510(k) clearance. This classification allows the company to bring the product to market more quickly than devices requiring full regulatory review .

How Can Patients Access the EYE7?

The EYE7 is available through Eyedaptic, though the company has not publicly disclosed pricing information. Patients interested in learning more about the device, including cost and availability, can contact Eyedaptic directly to request information. For current users of earlier Eyedaptic models looking to upgrade to the EYE7, the company's support team can assist with the transition .

One important consideration is insurance coverage. The EYE7 is not covered by standard health insurance plans. However, Eyedaptic noted that some patients may be eligible for partial reimbursement through VSP Vision, a vision care provider, or through the Department of Veterans Affairs for eligible veterans. These programs can help reduce out-of-pocket costs for patients who qualify .

The launch of the EYE7 represents a meaningful step forward in wearable AI technology for medical applications. By combining lightweight hardware with advanced artificial intelligence, Eyedaptic is addressing a real need for patients with vision loss who want to maintain independence and quality of life. The addition of Eva and the extended battery life make the device more practical for all-day use, while the ability to upgrade software remotely ensures that users can access new features without purchasing entirely new hardware.